Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

The White House is reportedly considering an executive order to fire thousands of HHS employees. If implemented within the ...

Robert F. Kennedy Jr.—whose history of anti-vaccine rhetoric has had the healthcare and biopharma industries on edge—was ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Cybersecurity must be a top priority for organizations in drug discovery/development due to the significant risks, including ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...